SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
+6.19%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$602M
AUM Growth
+$602M
(+8.4%)
Cap. Flow
+$7.84M
Cap. Flow
% of AUM
1.3%
Top 10 Holdings %
Top 10 Hldgs %
66.65%
Holding
35
New
5
Increased
14
Reduced
12
Closed
3
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$29.9M |
| 2 |
Gilead Sciences
GILD
|
$13.3M |
| 3 |
Merck
MRK
|
$11.4M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$9.83M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$5.23M |
Top Sells
| 1 |
Tenet Healthcare
THC
|
$14.9M |
| 2 |
Ironwood Pharmaceuticals
IRWD
|
$13.3M |
| 3 |
AGN
Allergan plc
AGN
|
$10.8M |
| 4 |
Boston Scientific
BSX
|
$9.16M |
| 5 |
Eli Lilly
LLY
|
$6.05M |
Sector Composition
| 1 | Healthcare | 98.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Abbott
ABT
$231B
| $64.9M | 10.79% | 1,064,562 -41,080 | -4% | -$2.51M |
|
|
2
Merck
MRK
$210B
| $55.5M | 9.22% | 913,830 +188,630 | +26% | +$11.4M |
|
3
Baxter International
BAX
$12.7B
| $53.2M | 8.85% | 721,058 +5,620 | +0.8% | +$415K |
|
|
4
Bristol-Myers Squibb
BMY
$96B
| $49.9M | 8.3% | 902,226 +540,220 | +149% | +$29.9M |
|
|
5
Boston Scientific
BSX
$156B
| $47.8M | 7.94% | 1,461,300 -280,080 | -16% | -$9.16M |
|
|
SHPG
6
DELISTED
Shire pic
SHPG
| $29M | 4.82% | 171,825 +6,850 | +4% | +$1.16M |
|
7
AstraZeneca
AZN
$248B
| $28.1M | 4.67% | 800,588 -5,447 | -0.7% | -$191K |
|
8
Revvity
RVTY
$10.5B
| $26.6M | 4.42% | 362,956 -15,250 | -4% | -$1.12M |
|
9
Bio-Rad Laboratories Class A
BIO
$8.06B
| $24.9M | 4.15% | 86,449 -7,791 | -8% | -$2.25M |
|
10
Integra LifeSciences
IART
$1.18B
| $21M | 3.5% | 326,659 -60,307 | -16% | -$3.88M |
|
11
Elevance Health
ELV
$71.8B
| $20.9M | 3.48% | 87,910 +2,000 | +2% | +$476K |
|
|
12
Gilead Sciences
GILD
$140B
| $20.7M | 3.43% | 291,600 +188,100 | +182% | +$13.3M |
|
|
NUVA
13
DELISTED
NuVasive, Inc.
NUVA
| $19.6M | 3.26% | 375,807 +3,810 | +1% | +$199K |
|
|
14
Eli Lilly
LLY
$657B
| $15.5M | 2.58% | 181,641 -70,873 | -28% | -$6.05M |
|
15
Perrigo
PRGO
$3.27B
| $14.5M | 2.42% | 199,440 +61,600 | +45% | +$4.49M |
|
16
Ionis Pharmaceuticals
IONS
$6.79B
| $12.6M | 2.1% | 303,240 +29,740 | +11% | +$1.24M |
|
17
Universal Health Services
UHS
$11.6B
| $11M | 1.83% | 98,633 +11,660 | +13% | +$1.3M |
|
18
Lexicon Pharmaceuticals
LXRX
$400M
| $10.4M | 1.72% | 862,602 +8,010 | +0.9% | +$96.1K |
|
|
19
Regeneron Pharmaceuticals
REGN
$61.5B
| $9.83M | 1.63% | +28,500 | New | +$9.83M |
|
20
Labcorp
LH
$23.1B
| $9.27M | 1.54% | 51,654 -32,746 | -39% | -$5.88M |
|
|
21
Ironwood Pharmaceuticals
IRWD
$214M
| $8.1M | 1.35% | 423,850 -697,285 | -62% | -$13.3M |
|
|
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
| $7.91M | 1.31% | 173,892 +50,000 | +40% | +$2.27M |
|
|
PTLA
23
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $7.58M | 1.26% | 200,800 +66,000 | +49% | +$2.49M |
|
|
PDCO
24
DELISTED
Patterson Companies, Inc.
PDCO
| $7.08M | 1.18% | 312,232 | – | – |
|
25
Cardinal Health
CAH
$35.5B
| $6.17M | 1.02% | 126,263 -100,000 | -44% | -$4.88M |
|